Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition containing gentiopicroside and preparation and usage thereof

A technology of gentiopicroside and pharmaceutical preparation, which is applied in the field of medicine and can solve the problems of long treatment period, unsatisfactory degree of cure of hepatitis, inaccurate treatment effect and the like

Inactive Publication Date: 2014-03-26
HARBIN GLORIA PHARMA
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But the degree of cure for hepatitis is far from satisfactory
Most of these drugs are oral preparations, and there are few injections. They all have the disadvantages of long treatment cycle and inaccurate therapeutic effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing gentiopicroside and preparation and usage thereof
  • Pharmaceutical composition containing gentiopicroside and preparation and usage thereof
  • Pharmaceutical composition containing gentiopicroside and preparation and usage thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Protective effect on apoptosis of isolated hepatocytes

[0057] Experimental animals: Kunming mice, male, 4 weeks old.

[0058] Test drug:

[0059] Test drug group 1: gentiopicroside 30mg / kg.

[0060] Test drug group 2: swertigin 30mg / kg.

[0061] Test drug group 3: gentiopicroside 27mg / kg, swertiroside 3mg / kg.

[0062] Test drug group 4: gentiopicroside 27.4mg / kg, swertigin 2.6mg / kg.

[0063]Test reagent: formaldehyde; CoulterDNA-PrepReagentsKit kit (DNA-PrepLPR fixative, DNA-Prepstain dye).

[0064] Test equipment: self-balancing microcentrifuge; flow cytometer.

[0065] Test method: the mice were randomly divided into normal control group, model group and test drug group. The administration group was given the corresponding drug by tail vein injection every day, and the dosage was 30 mg / kg. The normal control group and the model group were given the same volume of normal saline by tail vein injection every day for 7 consecutive days. Fasting (free drinking wate...

Embodiment 2

[0071] to CCl 4 Protective effect of acute liver injury in mice

[0072] Experimental animals: KM mice, grade: healthy second grade, age: 6.5±0.5 weeks, sex: half male and half female, body weight: 20±2g.

[0073] Test drug:

[0074] Test drug group 1: gentiopicroside 30mg / kg.

[0075] Test drug group 2: swertigin 30mg / kg.

[0076] Test drug group 3: gentiopicroside 27mg / kg, swertiroside 3mg / kg.

[0077] Test drug group 4: gentiopicroside 27.4mg / kg, swertigin 2.6mg / kg.

[0078] Test reagent: CCl 4 ;olive oil.

[0079] Test method: divide the mice into random groups according to body weight: blank control group, model group, test drug 1-4 groups, half male and half male. Each administration group was administered by the tail vein of the test drug group, and the blank control group and the model group were given equal volumes of distilled water, once a day, for 7 consecutive days. The food was withdrawn at 20:00 on the 6th day, the tail vein was administered once after w...

Embodiment 3

[0085] Protective effect on chronic liver injury in rats

[0086] Test animals: Wistar rats, male, body weight: 200±2g.

[0087] Test drug:

[0088] Test drug group 1: gentiopicroside 20mg / kg.

[0089] Test drug group 2: swertigin 20mg / kg.

[0090] Test drug group 3: gentiopicroside 18mg / kg, swertiroside 2mg / kg.

[0091] Test drug group 4: gentiopicroside 18.3 mg / kg, swertigin 1.7 mg / kg.

[0092] Test reagent: CCl 4 olive oil.

[0093] Test method: Rats were randomly divided into groups according to body weight: normal group, model group, and test drug group. Except for the blank control group, other groups were subcutaneously injected with 40% CCl 4 Olive oil solution 5ml / kg, then weekly subcutaneous injection of 40% CCl 4 Olive oil solution 3ml / kg twice for 6 weeks, the blank group was given the same volume of olive oil. At the same time, the other groups were given the same drug dose once a day through the tail vein for 6 weeks, weighed once a week, and adjusted th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medical technology and discloses a pharmaceutical composition containing gentiopicroside and a preparation and a usage thereof, wherein the pharmaceutical composition contains gentiopicroside and sweroside. The pharmaceutical composition is determined by scientific experiments. The experiments have proven that the sweroside generates no effect on the stability of the gentiopicroside, and pharmacological experiments have proven that the sweroside and the gentiopicroside have a synergistic effect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition containing gentiopicroside active ingredient, its preparation and application. Background technique [0002] The liver is an organ in the body that mainly has metabolic functions, and plays the roles of deoxidation, storage of glycogen, and synthesis of secreted proteins in the body. The liver is an important organ of the human body. Among them, hepatitis is a common and frequently-occurring disease. There are three main types: one is viral hepatitis, the other is alcoholic hepatitis, and the third is drug-induced hepatitis. Traditional Chinese medicine is collectively referred to as jaundice. The most common clinically is viral hepatitis. Hepatitis acute exacerbation period is often called "Yanghuang" in traditional Chinese medicine, and acute hepatitis turns into chronic hepatitis or primary chronic hepatitis is called "Yinhuang" in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P1/16A61P31/12A61P31/20A61P35/00
Inventor 朱吉满王禹夏瑞雪李开智
Owner HARBIN GLORIA PHARMA